Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Carcinoma of Unknown Primary Site
NCT00193622Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2004
- Primary completion
- Sep 2005
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in carcinoma of unknown primary (CUP), sponsored by SCRI Development Innovations. Primary endpoint: Overall response rate. Started Apr 2004; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00193622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193622.